ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 16.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 67,377 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,324 shares during the period. Public Sector Pension Investment Board owned approximately 0.31% of ANI Pharmaceuticals worth $6,172,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. boosted its stake in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after acquiring an additional 400 shares during the period. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth about $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ANIP shares. Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $103.43.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $77.81 on Thursday. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The stock’s 50 day moving average is $80.95 and its two-hundred day moving average is $86.30. The firm has a market capitalization of $1.75 billion, a PE ratio of 47.74 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares of the company’s stock, valued at $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director directly owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 4,322 shares of company stock valued at $354,816 in the last quarter. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.